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We have previously shown that NO•/cGMP signalling is
an important antihyper-trophic mechanism in the heart
[1-3]. HNO is the one electron reduction of NO•, thought
to elicit cardiovascular actions via cGMP and/or calcitonin
gene-related peptide (CGRP) [4]; we have recently shown
that the HNO donor Angeli's salt inhibits cardiomyocyte
hypertrophy and superoxide generation [5]. We now test
the hypothesis that isopropylamine/NO (IPA/NO) elicits
concentration-dependent anti-hypertrophic and antioxi-
dant actions via HNO/sGC/cGMP-dependent signalling.
IPA/NO (0.1–3 μM, replenished 3×/day over 48 h) elic-
ited concentration-dependent inhibition of endothelin-1
(ET1, 60 nM)-stimulated neonatal rat cardiomyocyte
(NRCM) hypertrophy (on two dimensional area of live
cells). At 3 μM, IPA/NO decreased cell size from 255 ±
28% to 96 ± 27% of paired control (n = 4, p < 0.001). This
antihypertrophic action of IPA/NO was significantly
attenuated in the presence of the HNO scavenger L-
cysteine (3 mM) or the cGMP-dependent protein kinase
inhibitor Rp-8 PCTP cGMPS (10 μM, both n = 4, p <
0.05), but was unaffected by the NO scavenger carboxy-
PTIO (200 μM) or the CGRP antagonist, CGRP8–37 (1 μM,
both n = 4). For comparison, the NO• donor DEA/NO
elicited similar concentration-dependent inhibition of
ET1-induced cardiomyocyte hypertrophy; this was inhib-
ited by carboxy-PTIO and Rp-8 PCTP cGMPS (10 μM,
both n = 4, p < 0.05), but was unaffected by L-cysteine.
Both IPA/NO and DEA/NO also blocked ET1-induced car-
diomyocyte superoxide generation (both n = 4, p < 0.001,
on NADPH-driven lucigenin-enhanced chemilumines-
cence), a key trigger of hypertrophy [3]. IPA-NO stimu-
lated purified cell-free sGC activity by 3.2 ± 0.6-fold, and
elevated NRCM cGMP content by 3.5 ± 0.4-fold (both n =
5, p < 0.05 via cGMP ELISA, as previously described [2,3].
None of these agents alone, or their respective vehicles,
elicited any effect on NRCM. Finally, using an NO•-sens-
ing electrode, we demonstrated that IPA/NO (in contrast
to DEA/NO), does not release NO• under these condi-
tions, even at supra-pharmacological concentrations. In
conclusion, these results provide convincing evidence that
IPA/NO prevents cardiomyocyte hypertrophy via HNO
activation of sGC. Although the antihypertrophic and
antioxidant efficacy of IPA/NO was comparable to NO•,
there is no role for extracellular oxidation of HNO to NO•
or CGRP-mediated signalling in these IPA/NO actions.
These studies may ultimately facilitate the development of
HNO donors such as IPA/NO as novel antihypertrophic
therapy for patients at risk of heart failure.
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